These considerations underscore the importance of a flexible, individualised approach to weight management when using GLP-1RAs
Of the 58 patients, 11 patients (19%) presented with low free carnitine levels at baseline and 47 (81%) patients presented with normal carnitine levels at baseline
Both drug classes have been shown to confer clinical benefits such as glycaemic control, body mass reduction, and improved systolic blood pressure and lipid profiles, which may collectively contribute to their cardiorenal protective effect.32 However, these drug classes use different mechanisms to achieve these effects
Growth hormone may produce greater total body composition changes due to simultaneous fat loss and muscle gain, but for individuals seeking pure fat reduction, AOD-9604 s targeted approach can be equally or more appropriate
For example: If a patient previously had an A1C 6.5 and now has an A1C of 6.0 on treatment , they still qualify for the diabetes indication